APOE4

Originally published July 20.

Originally published May 22.
Genentech is planning to study whether the investigational drug crenezumab can prevent Alzheimer's in a patient population genetically predisposed to get the degenerative disease.

"We are always looking at entities, particularly DTC companies, who may be marketing APOE tests without a sublicense from Athena, are making misleading representations of those tests and their clinical interpretations, and are generally violating patent claims we own and have licensed, accordingly," said a Duke spokesperson.

The "opt-in" model ensures that customers are aware of the risks and limitations of this potentially sensitive data, but some are questioning whether the direct-to-consumer model is the appropriate mechanism for delivering information on APOE status, even with additional precautions.